Cetuximab
| Evidence Level: L5 | Predicted Indications: 52 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Cetuximab |
| DrugBank ID | DB00002 |
| Brand Names (EU) | Erbitux |
| Evidence Level | L5 |
| Predicted Indications | 52 |
| Top Prediction Score | 99.95% |
Approved Indication (EMA)
Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer: in combination with irinotecan-based chemotherapy; in first-line in combination with FOLFOX; as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan. For details, see section 5.1. Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | ductal or ductular proliferation | 99.95% | DL |
| 2 | bronchial adenomas/carcinoids childhood | 99.95% | DL |
| 3 | chondroid hamartoma | 99.95% | DL |
| 4 | non-seminomatous lesion | 99.95% | DL |
| 5 | tumor of testis and paratestis | 99.95% | DL |
| 6 | odontogenic cyst | 99.95% | DL |
| 7 | thyroglossal duct cyst | 99.95% | DL |
| 8 | epiglottis neoplasm | 99.95% | DL |
| 9 | cystic neoplasm | 99.95% | DL |
| 10 | pre-malignant neoplasm | 99.95% | DL |
| 11 | benign neoplasm of tongue | 99.95% | DL |
| 12 | benign neoplasm of hypopharynx | 99.95% | DL |
| 13 | nasopharyngeal teratoma | 99.95% | DL |
| 14 | mesenchymoma | 99.95% | DL |
| 15 | benign neoplasm of floor of mouth | 99.95% | DL |
| 16 | cervical neuroblastoma | 99.95% | DL |
| 17 | inner ear neoplasm | 99.95% | DL |
| 18 | nasal cavity inverting papilloma | 99.95% | DL |
| 19 | schwannoma of jugular foramen | 99.95% | DL |
| 20 | epidural spinal canal neoplasm | 99.94% | DL |
Showing top 20 of 52 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.